Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

ClinicalTrials.gov ID: NCT00384033

Public ClinicalTrials.gov record NCT00384033. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.

Study identification

NCT ID
NCT00384033
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
638 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2006
Primary completion
Aug 31, 2007
Completion
Aug 31, 2007
Last update posted
Mar 14, 2012

2006 – 2007

United States locations

U.S. sites
22
U.S. states
11
U.S. cities
22
Facility City State ZIP Site status
Pfizer Investigational Site Beverly Hills California 90210
Pfizer Investigational Site Burbank California 91506
Pfizer Investigational Site Encino California 91316
Pfizer Investigational Site Los Alamitos California 90720
Pfizer Investigational Site Newport Beach California 92660
Pfizer Investigational Site Northridge California 91324
Pfizer Investigational Site Orange California 92868
Pfizer Investigational Site Pasadena California 91105
Pfizer Investigational Site Upland California 91786
Pfizer Investigational Site South Miami Florida 33143
Pfizer Investigational Site St. Petersburg Florida 33702
Pfizer Investigational Site Edwardsville Illinois 62025
Pfizer Investigational Site Farmington Hills Michigan 48336
Pfizer Investigational Site Flint Michigan 48507
Pfizer Investigational Site Okemos Michigan 48864
Pfizer Investigational Site Clementon New Jersey 08021
Pfizer Investigational Site Dayton Ohio 45408
Pfizer Investigational Site Portland Oregon 97210
Pfizer Investigational Site Philadelphia Pennsylvania 19149
Pfizer Investigational Site Salt Lake City Utah 84107
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Brown Deer Wisconsin 53223

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00384033, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 14, 2012 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00384033 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →